Opioid use disorder risk alleles in self-reported assigned African American/Afro-Caribbean and European biogeographical genetic ancestry groups and in males and females
Open Access
- 1 August 2024
- journal article
- research article
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 24 (4) , 1-6
Abstract
The influence of genetic variants related to opioid use disorder (OUD) was evaluated using multiple logistic regression analysis in self-reported assigned African American/Afro-Caribbean and European biogeographical ancestry groups (BGAGs) and by sex. From a sample size of 1301 adult patients (>18 years of age) seen in emergency departments of three medical centers in Ohio, six variants were found to be associated with OUD. Two of the variants, rs2740574 (CYP3A4) and rs324029 (DRD3), were included in the analysis having met criteria of at least five subjects for each BGAG, variant carrier status, and OUD status combinations. Variant carriers in the African/Afro-Caribbean BGAG had slightly lower predicted probabilities of OUD. Variant carriers in the European BGAG had slightly higher predicted probabilities of OUD. Relative to sex, all the six variants met evaluation criteria (five subjects for all sex, variant, and OUD status combinations). No statistically significant interactions were found between a given variant, BGAGs and sex. Findings suggest variant testing relative to OUD risk can be applied across BGAGs and sex, however, studies in larger populations are needed.Keywords
Funding Information
- Unrestricted grant from the Ohio Attorney General’s office
- Unrestricted grant from the Ohio Attorney General’s office
- Unrestricted grant from the Ohio Attorney General’s office
- Unrestricted grant from the Ohio Attorney General’s office
- Unrestricted grant from the Ohio Attorney General’s office.
- Unrestricted grant from the Ohio Attorney General’s office.
- Unrestricted grant from the Ohio Attorney General’s office.
- Unrestricted grant from the Ohio Attorney General’s office.
- Unrestricted grant from the Ohio Attorney General’s office.
- Unrestricted grant from the Ohio Attorney General’s office.
- Unrestricted grant from the Ohio Attorney General’s office.
- Unrestricted grant from the Ohio Attorney General’s office.
This publication has 27 references indexed in Scilit:
- Genetic Variants Associated With Opioid Use DisorderClinical Pharmacology & Therapeutics, 2023
- What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population sizeDrug and Alcohol Dependence Reports, 2022
- Emergency Department Visits for Nonfatal Opioid Overdose During the COVID-19 Pandemic Across Six US Health Care SystemsAnnals of Emergency Medicine, 2022
- Racial/ethnic differences in prescription opioid misuse and heroin use among a national sample, 1999–2018Drug and Alcohol Dependence, 2021
- A review of opioid addiction geneticsCurrent Opinion in Psychology, 2019
- Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic?Clinical Pharmacology & Therapeutics, 2019
- Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic ResearchClinical Pharmacology & Therapeutics, 2018
- CYP gene family variants as potential protective factors in drug addiction in Han ChineseThe Journal of Gene Medicine, 2016
- Relationship between the plasma fentanyl and serum 4β-hydroxycholesterol based on CYP3A5 genotype and gender in patients with cancer painDrug Metabolism and Pharmacokinetics, 2016
- DRD3 variation associates with early-onset heroin dependence, but not specific personality traitsProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2014